<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aratikatla, Eswar K.</style></author><author><style face="normal" font="default" size="100%">Bhattacharya, Asish K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Short review of synthetic routes for the antiepileptic drug (R)-lacosamide</style></title><secondary-title><style face="normal" font="default" size="100%">Organic Process Research &amp; Development</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">antiepileptic drug</style></keyword><keyword><style  face="normal" font="default" size="100%">epilepsy</style></keyword><keyword><style  face="normal" font="default" size="100%">lacosamide</style></keyword><keyword><style  face="normal" font="default" size="100%">serine derivative</style></keyword><keyword><style  face="normal" font="default" size="100%">synthesis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JAN</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">24</style></volume><pages><style face="normal" font="default" size="100%">17-24</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The disease epilepsy affects people of all ages and is due to a chronic neurological disorder in the brain. According to a report by the World Health Organization, epilepsy is one of the most common global neurological diseases. (R)-Lacosamide (Vimpat) was introduced by UCB Pharma in 2008 for the treatment of partial-onset seizures in patients suffering from epilepsy. This review summarizes all of the available synthetic strategies reported for (R)-lacosamide, which will help medicinal chemists in the further development of its synthesis.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Review</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;3.023&lt;/p&gt;
</style></custom4></record></records></xml>